Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)

NCT07000253 is registered in ClinicalTrials.gov with Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) as lead sponsor.

NCT NCT07000253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07000253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase
Phase 2
Overall status
Recruiting
Start date
April 29, 2026
Completion date
January 31, 2034
Enrollment
290 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, esophageal carcinoma, gastric (cardia, body) cancer, gastric (stomach) cancer, gastric adenocarcinoma, gastric adenocarcinoma or gastroesophageal junction adenocarcinoma or esophageal carcinoma